Evidence map›Paper›PMID 39131872›Full record

ArticleBladder cancer (Amsterdam, Netherlands)2024

Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis.

Burles A Johnson Iii, Benjamin A Teply, Catherine Kagemann, Bridget McGuire, Kara Lombardo, Yuezhou Jing, William Langbo, Jonathan I Epstein, George J Netto, Alex S Baras and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bladder cancer (Amsterdam, Netherlands), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Burles A Johnson IiiJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Benjamin A TeplyJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Catherine KagemannJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Bridget McGuireJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Kara LombardoThe Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA.
Yuezhou JingThe James Buchanan Brady Urological Institute, Baltimore, MD, USA.
William LangboJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Jonathan I EpsteinThe Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA.
George J NettoDepartment of Pathology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Alex S BarasThe Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA.
Andres MatosoJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
David J McConkeyJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Amol GuptaJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Nita AhujaDepartment of Surgery, Johns Hopkins University, Division of Surgical Oncology, Baltimore, MD, USA.
Ashley E RossThe James Buchanan Brady Urological Institute, Baltimore, MD, USA.
Phillip M PierorazioJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Eva ComperatDepartment of Pathology, Medical University of Vienna, Vienna, Austria.
Jean Hoffman-CensitsJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Nirmish SinglaJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Sunil H PatelThe Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA.
Max KatesThe Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA.
Woonyoung ChoiJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Trinity J BivalacquaJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Noah M HahnJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSarcomatoid urothelial cancer of the bladder (SBC) is a rare, but aggressive histological subtype for which novel treatments are needed.

objectiveWe evaluated the clinical activity and safety of neoadjuvant cisplatin plus gemcitabine plus docetaxel (CGD) in muscle-invasive patients with SBC and assessed SBC tumor biology by whole transcriptome RNA sequencing.

methodsA single-institution, retrospective analysis of muscle-invasive SBC patients treated with neoadjuvant CGD with molecular analysis. Patients received cisplatin 35 mg/m2 + gemcitabine 800 mg/m2 + docetaxel 35 mg/m2 intravenously on days 1 and 8 + pegfilgrastim 6 mg subcutaneously on day 9 every 3 weeks for 4 cycles followed by cystectomy. The primary endpoint was pathologic complete response (ypCR) rate.

resultsSixteen patients with SBC received neoadjuvant CGD with a ypCR rate of 38% and

conclusionsSBC is a chemosensitive subtype, with ypCR rate similar to urothelial bladder cancer following CGD neoadjuvant therapy. Whole transcriptome tissue analyses demonstrate increased expression of immune checkpoint and T-cell genes with therapeutic implications.

Indexed as

bladder cancercisplatincomplete responsedocetaxelgemcitabineneoadjuvantRNA sequencingSarcomatoid

Identifiers

PMID39131872
PMCPMC11308648

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.